These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26749690)

  • 1. Features of intestinal lesions in the clinical course of inflammatory bowel diseases.
    Vetuschi A; Latella G; Pompili S; Gaudio E; Sferra R
    Ital J Anat Embryol; 2014; 119(3):286-303. PubMed ID: 26749690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can we prevent, reduce or reverse intestinal fibrosis in IBD?
    Latella G; Sferra R; Speca S; Vetuschi A; Gaudio E
    Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1283-304. PubMed ID: 23740440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of initiation and progression of intestinal fibrosis in IBD.
    Latella G; Di Gregorio J; Flati V; Rieder F; Lawrance IC
    Scand J Gastroenterol; 2015 Jan; 50(1):53-65. PubMed ID: 25523556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory bowel disease in the pediatric patient.
    Ponsky T; Hindle A; Sandler A
    Surg Clin North Am; 2007 Jun; 87(3):643-58. PubMed ID: 17560417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.
    Sartor RB
    Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
    Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
    Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutic avenues for treatment of fibrosis: can we learn from other diseases?
    Rogler G
    Dig Dis; 2014; 32 Suppl 1():39-49. PubMed ID: 25531352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definition and epidemiology of inflammatory bowel disease.
    Fujii T; Watanabe M
    Nihon Rinsho; 2017 Mar; 75(3):357-363. PubMed ID: 30566774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants.
    Kruidenier L; Kuiper I; Lamers CB; Verspaget HW
    J Pathol; 2003 Sep; 201(1):28-36. PubMed ID: 12950014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy.
    Merga Y; Campbell BJ; Rhodes JM
    Dig Dis; 2014; 32(4):475-83. PubMed ID: 24969297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serologic markers in inflammatory bowel disease (IBD).
    Nakamura RM; Barry M
    MLO Med Lab Obs; 2001 Nov; 33(11):8-15; quiz 16-9. PubMed ID: 11721286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD.
    Latella G; Rogler G; Bamias G; Breynaert C; Florholmen J; Pellino G; Reif S; Speca S; Lawrance IC
    J Crohns Colitis; 2014 Oct; 8(10):1147-65. PubMed ID: 24731838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of non-inflammatory factors in intestinal fibrosis.
    Zhao JF; Ling FM; Li JR; Chen YD; Huang L; Zhu LR
    J Dig Dis; 2020 Jun; 21(6):315-318. PubMed ID: 32406603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokines in inflammatory bowel disease.
    Kmieć Z
    Arch Immunol Ther Exp (Warsz); 1998; 46(3):143-55. PubMed ID: 9704146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical study of chymase-positive mast cells in inflammatory bowel disease.
    Andoh A; Deguchi Y; Inatomi O; Yagi Y; Bamba S; Tsujikawa T; Fujiyama Y
    Oncol Rep; 2006 Jul; 16(1):103-7. PubMed ID: 16786130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of tissue remodeling in inflammatory bowel disease.
    Rieder F; Fiocchi C
    Dig Dis; 2013; 31(2):186-93. PubMed ID: 24030223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of animal models for the pathogenesis and treatment of inflammatory bowel disease.
    Dieleman LA; Peña AS; Meuwissen SG; van Rees EP
    Scand J Gastroenterol Suppl; 1997; 223():99-104. PubMed ID: 9200314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A primary dysregulation in the immunoregulatory role of the intestinal mucosal epithelial cell in inflammatory bowel disease pathogenesis? Biology of inflammatory response as tissue pattern entities in Crohn's versus ulcerative colitis.
    Agius LM
    J Theor Biol; 2004 Mar; 227(2):219-28. PubMed ID: 14990386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Circadian rhythm and inflammatory bowel disease].
    Takagi T; Inada Y; Naito Y
    Nihon Rinsho; 2013 Dec; 71(12):2165-70. PubMed ID: 24437273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.